JAMA Oncology
Brief Report
April 25, 2024
Giacomo听Montagna,听MD, MPH; Mary M.听Mrdutt,听MD, MS; Susie X.听Sun,听MD; Callie听Hlavin,听MD, MPH; Emilia J.听Diego,听MD; Stephanie M.听Wong,听MD, MPH; Andrea V.听Barrio,听MD; Astrid Botty听van den Bruele,听MD; Neslihan听Cabioglu,听MD, PhD; Varadan听Sevilimedu,听MBBS, DrPH; Laura H.听Rosenberger,听MD, MS; E. Shelley听Hwang,听MD, MPH; Abigail听Ingham,听MBchB; B盲rbel听Papassotiropoulos,听MD; Bich Doan听Nguyen-Str盲uli,听MD; Christian听Kurzeder,听MD; Danilo D铆az听Aybar,听MD; Denise听Vorburger,听MD; Dieter Michael听Matlac,听MD; Edvin听Ostapenko,听MD; Fabian听Riedel,听MD; Florian听Fitzal,听MD; Francesco听Meani,听MD; Franziska听Fick,听MD; Jacqueline听Sagasser,听MD; J枚rg听Heil,听MD, PhD; Hasan听Karanl谋k,听MD; Konstantin J.听Dedes,听MD; Laszlo听Romics,听MD, PhD; Maggie听Banys-Paluchowski,听MD, PhD; Mahmut听Muslumanoglu,听MD; Maria Del Rosario Cueva听Perez,听MD; Marcelo Ch谩vez听D铆az,听MD; Martin听Heidinger,听MD; Mathias K.听Fehr,听MD; Mattea听Reinisch,听MD; Mustafa听Tukenmez,听MD; Nadia听Maggi,听MD; Nicola听Rocco,听MD, PhD; Nina听Ditsch,听MD, PhD; Oreste Davide听Gentilini,听MD; Regis R.听Paulinelli,听MD, PhD; Sebasti谩n Sol茅听Zarhi,听MD; Sherko听Kuemmel,听MD, PhD; Simona听Bruzas,听MD; Simona听di Lascio,听MD; Tamara K.听Parissenti,听MD; Tanya L.听Hoskin,听MS; Uwe听G眉th,听MD; Valentina听Ovalle,听MD; Christoph听Tausch,听MD; Henry M.听Kuerer,听MD, PhD; Abigail S.听Caudle,听MD; Jean-Francois听Boileau,听MD, MSc; Judy C.听Boughey,听MD; Thorsten听K眉hn,听MD, PhD; Monica听Morrow,听MD; Walter P.听Weber,听MD
online first
JAMA Oncol. 2024; 10.1001/jamaoncol.2024.0578
This cohort study examines oncological outcomes after sentinel lymph node biopsy with dual-tracer mapping or targeted axillary dissection.
JAMA Surgery
Original Investigation
June 7, 2023
Sherko听Kuemmel,听MD, PhD; Joerg听Heil,听MD, PhD; Simona听Bruzas,听MD; Elisabeth听Breit,听PhD, BSc; Dorothea听Schindowski; Hakima听Harrach,听MD; Ouafaa听Chiari,听MD; Karin听Hellerhoff,听MD; Elena听Bensmann,听MD; Volker听Hanf,听MD, PhD; Sven-Thomas听Gra脽hoff,听MD; Petra听Deuschle,听MD; Kerstin听Belke,听MD; Silke听Polata,听MD; Stefan听Paepke,听MD; Mathias听Warm,听MD, PhD; Johannes听Meiler,听MD; Christian听Schindlbeck,听MD, PhD; Wencke听Ruhwedel,听MD; Ulrike听Beckmann,听MD; Ulrich听Groh,听MD; Peter听Dall,听MD, PhD; Jens-Uwe听Blohmer,听MD, PhD; Alexander听Traut,听MD; Mattea听Reinisch,听MD
JAMA Surg. 2023; 158(8):807-815. 10.1001/jamasurg.2023.1772
This cohort study assesses 3-year clinical outcomes in patients with node-positive breast cancer who underwent targeted axillary dissection alone or in combination with axillary lymph node dissection.
JAMA Oncology
Original Investigation
May 11, 2023
Oleg听Gluz,听MD; Ulrike A.听Nitz,听MD; Matthias听Christgen,听MD, PhD; Sherko听Kuemmel,听MD, PhD; Johannes听Holtschmidt,听MD; Johannes听Schumacher,听PhD; Andreas听Hartkopf,听MD; Jochem听Potenberg,听MD; Kerstin听L眉edtke-Heckenkamp,听MD; Marianne听Just,听MD; Christian听Schem,听MD, PhD; Raquel听von Schumann,听MD; Cornelia听Kolberg-Liedtke,听MD, PhD; Christine Zu听Eulenburg,听PhD; Timo听Schink枚the,听MD, PhD; Monika听Graeser,听MD; Rachel听Wuerstlein,听MD; Ronald E.听Kates,听PhD; Hans Heinrich听Kreipe,听MD, PhD; Nadia听Harbeck,听MD, PhD
free access
JAMA Oncol. 2023; 9(7):946-954. 10.1001/jamaoncol.2023.0646
This randomized clinical trial aims to determine whether neoadjuvant de-escalated chemotherapy is superior to endocrine therapy, both in combination with pertuzumab and trastuzumab, in a highly heterogeneous hormone receptor鈥損ositive/ERBB2-positive early breast cancer.
JAMA Oncology
Original Investigation
August 29, 2019
Peter听Schmid,听FRCP, PhD; Matthias听Zaiss,听MD; Catherine听Harper-Wynne,听MD; Marta听Ferreira,听MD; Sidharth听Dubey,听FRCR; Stephen听Chan,听FRCP, DM; Andreas听Makris,听FRCP; Gia听Nemsadze,听MD, PhD; Adrian M.听Brunt,听FRCP; Sherko听Kuemmel,听MD, PhD; Isabel听Ruiz,听MD; Antonia听Perell贸,听MD; Anne听Kendall,听MD; Janet听Brown,听MD; Hartmut听Kristeleit,听FRCP; John听Conibear,听MD; Cristina听Saura,听MD; Julien听Grenier,听MD; K谩roly听M谩hr,听MD; Michael听Schenker,听MD, PhD; Joohyuk听Sohn,听MD, PhD; Keun Seok听Lee,听MD, PhD; Christopher J.听Shepherd,听PhD; Elisabeth听Oelmann,听MD, PhD; Shah-Jalal听Sarker,听PhD; Aaron听Prendergast,听MSc; Patricia听Marosics,听BSc; Atiyyah听Moosa,听BSc; Cheryl听Lawrence,听BPharm; Carike听Coetzee,听MSc; Kelly听Mousa,听MSc; Javier听Cort茅s,听MD, PhD
open access
JAMA Oncol. 2019; 5(11):1556-1564. 10.1001/jamaoncol.2019.2526
This open-label phase 2 randomized clinical trial evaluates the safety and efficacy of vistusertib in combination with fulvestrant compared with fulvestrant alone or fulvestrant plus everolimus for women with hormone receptor鈥損ositive metastatic breast cancer.